课题基金 / 基金详情

Preclinical models of natural killer cell-based immunotherapy to cure refractory childhood acute lymphoblastic leukemia

Preclinical models of natural killer cell-based immunotherapy to cure refractory childhood acute lymphoblastic leukemia
基于自然杀伤细胞的免疫疗法治疗难治性儿童急性淋巴细胞白血病的临床前模型
批准号:
279959
负责人:
Duval Michel
金额:
$24.18万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-03-01 至 2016-03-01

项目摘要

项目成果

Duval Michel的其他基金

相似基金

相关文献

中文摘要
翻译
治疗后白血病复发的儿童中有40%到50%死于疾病,这表明迫切需要改进目前的治疗方法。治愈这些孩子的唯一希望是高强度的高毒性化疗,然后是t
英文摘要
Forty to fifty percent of children whose leukemia reappears following treatment die of their disease, underscoring an urgent need to improve current therapies. The only hope of a cure for these children is intensive highly toxic chemotherapy followed by t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase I first-in-human trial for ThINKK adoptive immunotherapy in children with high-risk cancers
Phase I first-in-human trial of ThINKK adoptive immunotherapy in children with high-risk cancers
Toward the cure of neuroblastoma: innovative immunotherapeutic approaches
海外基金